Guy G. De Backer - Public Health

Author Information

Guy G. De Backer is a distinguished researcher affiliated with the Department of Public Health and Primary Care at Ghent University, Ghent, Belgium. With an extensive background in public health, his research primarily focuses on cardiovascular diseases, dyslipidemia, and hypertension. His contributions to these fields are vital in shaping healthcare guidelines and improving patient outcomes.

Research Contributions

Guy G. De Backer has made significant contributions to public health, particularly in the areas of cardiovascular disease and dyslipidemia management. His research includes studies on dyslipidemia management in patients with coronary artery disease, worldwide trends in hypertension prevalence, and the use of models to estimate the total risk of developing atherosclerotic cardiovascular disease. His work is highly influential in translating scientific findings into practical guidelines for better disease prevention and control.

Aliases

Guy G. De Backer is also known by several aliases, including Guy Backer, Guy De Backer, G. Backer, G De Backer, and G. De Backer. These aliases are used interchangeably in various publications and citations.

Publication and Citation Metrics

Metric	Value
Citation Count	20617
h-Index	34
Paper Count	245

Publications:

Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey

DOI: 10.3390/jcm10163711

Year: 2021

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

DOI: 10.1016/S0140-6736(21)01330-1

Year: 2021

On the use of models to estimate the total risk of developing atherosclerotic cardiovascular disease

DOI: 10.1177/2047487320902747

Year: 2020

Prevention of atherosclerotic cardiovascular disease is possible but poorly put into practice.

DOI: 10.33963/KP.15382

Year: 2020

Translating science into guidance on the management of dyslipidaemias.

DOI: 10.1016/J.ATHEROSCLEROSIS.2020.10.894

Year: 2020

Author response: Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

DOI: 10.7554/ELIFE.60060.SA2

Year: 2020

Risk scoring in primary prevention of atherosclerotic cardiovascular disease: Strengths and limitations.

DOI: 10.1177/2047487319847007

Year: 2019

Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study

DOI: 10.1177/2047487319874898

Year: 2019

Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

DOI: 10.1016/j.atherosclerosis.2019.11.020

Year: 2019

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

DOI:

Year: 2019

What Are the Key Provisions of HIPAA?

Who is Eligible for the COVID-19 Vaccine?

What is a Virus?

What are Foodborne Diseases?

Are There Successful Examples of Bridging the Digital Divide?

How Can Families Be Supported?

What Role Does Research Play?

What are Mobile Health Apps?

How Did the Pandemic Affect Mental Health?

What are Mycotoxins?

Partnered Content Networks

Relevant Topics